Active Ingredient: bictegravir, emtricitabine, and tenofovir alafenamideStrength: 50 mg of BIC, 200 mg of FTC, and 25 mg of TAF/ 30 mg of BIC, 120 mg of FTC, and 15 mg of TAFDosage Form: TabletMechanism of Action: HIV reverse transcriptase inhibitorsFirst Approval: US (07 Feb 2018), EU (25 Jun 2018)Revenue1Gilead's HIV drug, Biktarvy has…
